Mike Sismour, Ph.D. has joined Ultivue in the role of Vice President, Research, and Mark Rees, Ph.D. has joined as Vice President, Corporate Development.
Mike has a background enabling innovative solutions in the biotechnology and diagnostics industries. He brings extensive experience in nucleic acid chemistry/enzymology, in situ biomolecule detection, multiplexed biomolecule analysis, and sequencing system development. He was an NIH Ruth L. Kirschstein Postdoctoral Fellow at Harvard Medical School, a fellow at the Wyss Institute at Harvard, and most recently was Chief Scientist/Head of Genomics R&D at Beckman Coulter Life Science.
“Ultivue has an amazing technology platform and I am very excited to join their growing team,” says Mike. “Their innovations are pushing boundaries in what is technically achievable in complex assays while bringing a robust, simple solution to the customer.”
Mark joins Ultivue with over two decades of leadership experience in scientific affairs and business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform, as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs, and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher), and Novocastra Laboratories.
According to Mark, “I am very excited to be joining the executive team at Ultivue. Ultivue has the best in class multiplex IF technology platform, which together with their rapid custom service, can deliver high-quality complex assay solutions to Biopharma and CRO partners in record turnaround times.”
“It’s an exciting time for us at Ultivue,” notes Jacques Corriveau, President, and CEO. “The combination of Mike’s ability to iterate on current technology and innovate on future offerings, alongside Mark further enabling these advancements within our partnership ecosystem, will help our customers bring exciting new therapies to market and positively impact the drive for personalized cancer treatment.”
